MusclePharm (OTCMKTS:MSLP – Get Free Report) and AEON Biopharma (NASDAQ:AEON – Get Free Report) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Earnings and Valuation
This table compares MusclePharm and AEON Biopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MusclePharm | $50.04 million | 0.00 | -$12.87 million | ($0.58) | N/A |
| AEON Biopharma | N/A | N/A | -$36.63 million | ($2.43) | -0.45 |
Risk and Volatility
MusclePharm has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
Profitability
This table compares MusclePharm and AEON Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MusclePharm | -38.51% | N/A | -169.56% |
| AEON Biopharma | N/A | N/A | -994.63% |
Institutional and Insider Ownership
15.5% of MusclePharm shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 60.7% of MusclePharm shares are held by insiders. Comparatively, 0.9% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and recommmendations for MusclePharm and AEON Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MusclePharm | 0 | 0 | 0 | 0 | 0.00 |
| AEON Biopharma | 0 | 1 | 1 | 1 | 3.00 |
Given MusclePharm’s higher probable upside, research analysts plainly believe MusclePharm is more favorable than AEON Biopharma.
Summary
AEON Biopharma beats MusclePharm on 7 of the 13 factors compared between the two stocks.
About MusclePharm
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
About AEON Biopharma
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
